OmniAb (OABI) Depreciation & Amortization (CF) (2022 - 2026)
OmniAb's (OABI) quarterly Depreciation & Amortization (CF) came in at $606000.0 in Q1 2026, down 87.22% year-on-year from $4.7 million in Q1 2025, and down 92.14% on a QoQ basis from $7.7 million in Q4 2025.
OmniAb (OABI) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
OmniAb (OABI) has 5 years of Depreciation & Amortization (CF) data on file, last reported at $606000.0 in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 87.22% year-over-year to $606000.0 in Q1 2026; TTM through Mar 2026 was $17.6 million, a 24.64% decrease from a year earlier, with the FY2025 full-year figure at $21.8 million, down 7.76% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $606000.0, down from $7.7 million in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for OABI reached as high as $7.7 million in Q4 2025 and fell as low as $606000.0 in Q1 2026.
- Historically, Depreciation & Amortization (CF) has averaged $4.9 million across 5 years, with a median of $4.8 million in 2023.
- Across the five-year window, Depreciation & Amortization (CF) surged 54.15% in 2024 and plunged 87.22% in 2026, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $4.8 million in 2022, then grew by 2.37% to $4.9 million in 2023, then soared by 54.15% to $7.6 million in 2024, then rose by 1.33% to $7.7 million in 2025, then sank by 92.14% to $606000.0 in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $606000.0 in Q1 2026, $7.7 million in Q4 2025, and $4.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | OmniAb | 261.62 Mn | 212.55 Mn | 14.41 Mn | 606,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 606,000.00 |
| Mar 31, 2026 | 606,000.00 |
| Dec 31, 2025 | 7.71 Mn |
| Dec 31, 2025 | 7.71 Mn |
| Sep 30, 2025 | 4.66 Mn |
| Sep 30, 2025 | 4.66 Mn |
| Jun 30, 2025 | 4.65 Mn |
| Jun 30, 2025 | 4.65 Mn |
| Mar 31, 2025 | 4.74 Mn |
| Mar 31, 2025 | 4.74 Mn |
| Dec 31, 2024 | 7.61 Mn |
| Dec 31, 2024 | 7.61 Mn |
| Sep 30, 2024 | 4.93 Mn |
| Sep 30, 2024 | 4.93 Mn |
| Jun 30, 2024 | 6.10 Mn |
| Jun 30, 2024 | 6.10 Mn |
| Mar 31, 2024 | 4.95 Mn |
| Mar 31, 2024 | 4.95 Mn |
| Dec 31, 2023 | 4.93 Mn |
| Dec 31, 2023 | 4.93 Mn |